Michael Bishop

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael Bishop, Constantine S. Tam et al. · New England Journal of Medicine · 2018 · 4K citations · Full text

Medicine, Hematology, Oncology +15

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Hematology, Oncology +9

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.

Deborah L. Darrington, Julie M. Vose, J R Anderson et al. · Journal of Clinical Oncology · 1994 · 338 citations

Medicine, Hematology, Oncology +17

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States

Jeffrey I. Cohen, Elaine S. Jaffe, Janet K. Dale et al. · Blood · 2011 · 308 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +7

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.

Philip J. Bierman, Julie M. Vose, J R Anderson et al. · Journal of Clinical Oncology · 1997 · 229 citations

Medicine, Hematology, Oncology +16